亚洲色图国产,国内精品久久久久久久影视简单,激情四射五月天婷婷,中日韩欧美精彩视频,av高清免费,国产91电影在线观看,日本免费三片在线播放

關(guān)于我們
研發(fā)服務(wù)
服務(wù)平臺(tái)
客戶中心
新聞資訊
投資者關(guān)系
人力資源
EN
×
EN

  • 業(yè)務(wù)咨詢

    中國(guó)：

    Email: marketing@medicilon.com.cn

    業(yè)務(wù)咨詢專線：400-780-8018

    （僅限服務(wù)咨詢，其他事宜請(qǐng)撥打川沙總部電話）

    川沙總部電話: +86 (21) 5859-1500

    海外：

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com
在線留言×
點(diǎn)擊切換

搜索結(jié)果包含 maximum tolerated dose 的內(nèi)容

Jul 06,2023
PTX-HSN是一種高效納米系統(tǒng)，具有較高耐受劑量，可將PTX遞送至卵巢癌并增強(qiáng)主動(dòng)腫瘤靶向性。此研究中所有體內(nèi)實(shí)驗(yàn)均通過(guò)美迪西進(jìn)行
Paclitaxel-loaded hyaluronan solid nanoemulsions (PTX-HSNs) were successfully fabricated for the delivery of PTX to improve ovarian cancer treatment via active tumor targeting. The in vivo #toxicity,
查看更多
PTX-HSN是一種高效納米系統(tǒng)，具有較高耐受劑量，可將PTX遞送至卵巢癌并增強(qiáng)主動(dòng)腫瘤靶向性。此研究中所有體內(nèi)實(shí)驗(yàn)均通過(guò)美迪西進(jìn)行
Jul 06,2023
研究人員成功發(fā)現(xiàn)了一種口服PROTAC降解劑SIAIS164018，具有良好的體內(nèi)耐受性。PK和MTD研究通過(guò)美迪西進(jìn)行
PROTAC is an attractive technology in drug discovery. Researchers successfully discovered an orally available PROTAC degrader SIAIS164018 which degrades not only ALK or mutant EGFR but also oncoprotei
查看更多
研究人員成功發(fā)現(xiàn)了一種口服PROTAC降解劑SIAIS164018，具有良好的體內(nèi)耐受性。PK和MTD研究通過(guò)美迪西進(jìn)行
Jun 28,2023
SAHA可有效恢復(fù)阿爾茨海默病模型的記憶能力，本研究中SAHA通過(guò)美迪西合成
SAHA was synthesized by Medicilon and was given to mice as 50?mg/kg doses. Injections (10?mL/kg) were given intraperitoneally and were alternated daily between left and right sides of the abdomen. Chronic treatments of SAHA completely restored performance
查看更多
SAHA可有效恢復(fù)阿爾茨海默病模型的記憶能力，本研究中SAHA通過(guò)美迪西合成
Jun 28,2023
法尼基轉(zhuǎn)移酶抑制劑LNK-754單次口服后即可快速穿過(guò)血腦屏障，本研究中PK分析通過(guò)美迪西進(jìn)行
Pharmacokinetic studies revealed that after a single oral dose, the FTI (LNK-754) was cleared from plasma within 20 hours and could rapidly cross the blood-brain-barrier. Pharmacokinetic analysis was performed as a service provided by Medicilon.
查看更多
法尼基轉(zhuǎn)移酶抑制劑LNK-754單次口服后即可快速穿過(guò)血腦屏障，本研究中PK分析通過(guò)美迪西進(jìn)行
Jun 28,2023
WYC-209可抑制惡性小鼠黑色素瘤腫瘤再生細(xì)胞增殖，本研究中SPR通過(guò)美迪西使用Biacore 8K進(jìn)行
The binding assay by surface plasmon resonance (SPR) analysis shows that WYC-209A and WYC-209B acid bind to RARs at nano-molar doses. SPR was carried out by Medicilon, using the Biacore 8K equipment.
查看更多
WYC-209可抑制惡性小鼠黑色素瘤腫瘤再生細(xì)胞增殖，本研究中SPR通過(guò)美迪西使用Biacore 8K進(jìn)行
×
搜索驗(yàn)證
點(diǎn)擊切換